Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder
about
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasmsEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationOncogenic Kras initiates leukemia in hematopoietic stem cellsRAS diseases in childrenNeurofibromatosis type 1 - a model for nervous system tumour formation?Oncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosisKnock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelOptimizing biologically targeted clinical trials for neurofibromatosis.Cardiac and vascular functions of the zebrafish orthologues of the type I neurofibromatosis gene NFI.Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.Response and resistance to MEK inhibition in leukaemias initiated by hyperactive RasConstitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.Harnessing preclinical mouse models to inform human clinical cancer trials.Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease.Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency.The epigenetic regulator CXXC finger protein 1 is essential for murine hematopoiesis.Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant miceModulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative diseasePTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant miceSchweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cellsFunctional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.Scientific and clinical opportunities for modeling blood disorders with embryonic stem cellsAbnormal hematopoiesis in Gab2 mutant miceDeficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formationTargeting oncogenic Ras signaling in hematologic malignancies.Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemiaNf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.Regulation of Ras signal transduction during T cell development and activation.Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
P2860
Q24530021-27A7FF82-BA57-44B2-A4E5-310B53955A12Q26828777-A69FF9DE-0D8B-46E2-BF65-9F7225412831Q26851000-7C2D3A48-5DCB-40EC-B506-91526C38D8A3Q27331698-EC24DD8E-0B95-4C6B-924F-1EFC11106CC7Q28252058-7C1B4082-6557-4A91-9E9D-05DCED287E30Q28265284-B9B50F83-C6AF-45C1-92F6-8B50FF996AA9Q28589373-2AC68489-49D7-451F-8A2B-DC0E05A63504Q28590872-24F78F8B-F01F-4A38-8268-19AC54D04451Q30438898-3131BEB5-03CF-4955-A85B-D02FFA635A57Q30492592-822D2217-8B2B-464D-BE15-35D55E7D2ACBQ33394269-588123F3-86F0-434D-BEA1-5963684DE0BCQ33884193-9D154B9D-029B-432E-AF2E-6E6479F981D4Q33896721-DEBAB166-1C2F-4941-B46A-88E2C8ABAD28Q33993387-7537736D-C1F9-46EB-84FC-FBF0646C09F4Q34099193-21C79E7C-0E2C-4935-ABBF-7B959578524BQ34130332-D44ED344-4F59-4B74-88A9-69465563671AQ34310556-BFBBF49C-2F9F-4520-9B8A-81D66938E247Q34386922-15F56620-C5DA-4776-90B7-FA29D0CBE928Q34498952-E9BEB8AE-6957-4AF1-AAE4-4028EA4333E3Q34541593-DD0CA673-7200-4BDF-8190-9EA44F2CC703Q34572866-84745877-166D-44FF-A706-01384E68D099Q34625800-A47C3D86-2442-4478-AEBC-913622DC7448Q34799331-67FDABB3-BCD5-47F7-8426-2CA62791D7D7Q35081389-A124592E-A6A7-4616-BCC2-5A07F9A6EAA9Q35615842-2698EF1E-B852-4E97-B705-D074E1277C9DQ35616065-2BC159CC-54EF-4254-8F57-8B86C43F9DC5Q35628894-AD187615-A7FD-49FC-B116-811BFB7CD4A7Q35711858-8B25153D-34B7-4F3A-9326-199ECCACE98DQ35804477-5EC8B9F0-359D-4BC1-B7F3-97A64A5C6B04Q35847802-8F649DF3-CE19-495A-8B7E-79B3B92FA3B2Q35848553-409DBD7D-F69C-4EF3-8443-5692F45F13E0Q35850643-F2A2DB54-157D-4341-8D50-6EA9C99ABF64Q35905350-3129AEAE-86A2-446A-AF6B-2590F9AF3071Q35987653-DCCD8292-F9D7-4D34-B763-15B93E1026F5Q36298172-FC0727EB-02DD-45E9-9D0E-EB2F6412E353Q36352506-5C29531D-F310-428C-BCCB-3845C2ECB594Q36407156-843F5339-E98D-4A77-A50A-D967FF2FE07DQ36422351-4184B790-677D-4D58-9D09-FAF62969F269Q36435627-AF9DAED9-2BD5-4FF4-9414-D995AD21DDB1Q36497201-31089D00-3CC3-42E0-A367-0C2CA724B43B
P2860
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder
description
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im Juni 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2004/06/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/06/01)
@nl
наукова стаття, опублікована в червні 2004
@uk
مقالة علمية (نشرت في يونيو 2004)
@ar
name
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@ast
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@en
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@nl
type
label
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@ast
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@en
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@nl
prefLabel
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@ast
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@en
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@nl
P2093
P1433
P1476
Somatic inactivation of Nf1 in ...... ve myeloproliferative disorder
@en
P2093
Abigail Aiyigari
Benjamin S. Braun
Doan T. Le
Jennifer O. Lauchle
Kevin M. Shannon
Luis Parada
Michelle M. Le Beau
Namie Kong
Scott C. Kogan
P304
P356
10.1182/BLOOD-2003-08-2650
P407
P577
2004-06-01T00:00:00Z